<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.1 20151215//EN" "JATS-archivearticle1.dtd"> 
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><?properties open_access?><?DTDIdentifier.IdentifierValue -//NPG//DTD XML Article//EN?><?DTDIdentifier.IdentifierType public?><?SourceDTD.DTDName NPG_XML_Article.dtd?><?SourceDTD.Version 2.7.10?><?ConverterInfo.XSLTName nature2nlmx2.xsl?><?ConverterInfo.Version 2?><front><journal-meta><journal-id journal-id-type="nlm-ta">Sci Rep</journal-id><journal-id journal-id-type="iso-abbrev">Sci Rep</journal-id><journal-title-group><journal-title>Scientific Reports</journal-title></journal-title-group><issn pub-type="epub">2045-2322</issn><publisher><publisher-name>Nature Publishing Group</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">4823696</article-id><article-id pub-id-type="pii">srep24160</article-id><article-id pub-id-type="doi">10.1038/srep24160</article-id><article-categories><subj-group subj-group-type="heading"><subject>Article</subject></subj-group></article-categories><title-group><article-title>Deletion and low expression of <italic>NFKBIA</italic> are associated with poor prognosis in lower-grade glioma patients</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Kinker</surname><given-names>Gabriela Sarti</given-names></name><xref ref-type="aff" rid="a1">1</xref></contrib><contrib contrib-type="author"><name><surname>Thomas</surname><given-names>Andrew Maltez</given-names></name><xref ref-type="aff" rid="a2">2</xref><xref ref-type="aff" rid="a3">3</xref><xref ref-type="aff" rid="a4">4</xref></contrib><contrib contrib-type="author"><name><surname>Carvalho</surname><given-names>Vinicius Jardim</given-names></name><xref ref-type="aff" rid="a3">3</xref><xref ref-type="aff" rid="a5">5</xref></contrib><contrib contrib-type="author"><name><surname>Lima</surname><given-names>Felipe Prata</given-names></name><xref ref-type="aff" rid="a2">2</xref><xref ref-type="aff" rid="a3">3</xref><xref ref-type="aff" rid="a6">6</xref></contrib><contrib contrib-type="author"><name><surname>Fujita</surname><given-names>Andr&#x000e9;</given-names></name><xref ref-type="corresp" rid="c1">a</xref><xref ref-type="aff" rid="a7">7</xref></contrib><aff id="a1"><label>1</label><institution>Department of Physiology, Institute of Bioscience, University of S&#x000e3;o Paulo</institution>, S&#x000e3;o Paulo, <country>Brazil</country></aff><aff id="a2"><label>2</label><institution>Department of Biochemistry, Institute of Chemistry, University of S&#x000e3;o Paulo</institution>, S&#x000e3;o Paulo, <country>Brazil</country></aff><aff id="a3"><label>3</label><institution>Bioinformatics Graduate Program,University of S&#x000e3;o Paulo</institution>, S&#x000e3;o Paulo, <country>Brazil</country></aff><aff id="a4"><label>4</label><institution>Medical Genomics Laboratory, International Research Center, AC Camargo Cancer Center</institution>, S&#x000e3;o Paulo, <country>Brazil</country></aff><aff id="a5"><label>5</label><institution>Department of Botany, Institute of Bioscience, University of S&#x000e3;o Paulo</institution>, S&#x000e3;o Paulo, <country>Brazil</country></aff><aff id="a6"><label>6</label><institution>Federal Institute of Alagoas</institution>, Alagoas, <country>Brazil</country></aff><aff id="a7"><label>7</label><institution>Department of Computer Science, Institute of Mathematics and Statistics, University of S&#x000e3;o Paulo</institution>, S&#x000e3;o Paulo, <country>Brazil</country></aff></contrib-group><author-notes><corresp id="c1"><label>a</label><email>fujita@ime.usp.br</email></corresp></author-notes><pub-date pub-type="epub"><day>07</day><month>04</month><year>2016</year></pub-date><pub-date pub-type="collection"><year>2016</year></pub-date><volume>6</volume><elocation-id>24160</elocation-id><history><date date-type="received"><day>21</day><month>12</month><year>2015</year></date><date date-type="accepted"><day>21</day><month>03</month><year>2016</year></date></history><permissions><copyright-statement>Copyright &#x000a9; 2016, Macmillan Publishers Limited</copyright-statement><copyright-year>2016</copyright-year><copyright-holder>Macmillan Publishers Limited</copyright-holder><license xmlns:xlink="http://www.w3.org/1999/xlink" license-type="open-access" xlink:href="http://creativecommons.org/licenses/by/4.0/"><!--author-paid--><license-p>This work is licensed under a Creative Commons Attribution 4.0 International License. The images or other third party material in this article are included in the article&#x02019;s Creative Commons license, unless indicated otherwise in the credit line; if the material is not included under the Creative Commons license, users will need to obtain permission from the license holder to reproduce the material. To view a copy of this license, visit <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">http://creativecommons.org/licenses/by/4.0/</ext-link></license-p></license></permissions><abstract><p>Lower-grade gliomas (LGGs), which are uniformly fatal in young adults, are classified as grades II-III tumors according to their histological features. The NF&#x003ba;B transcription factor, a crucial player in cancer initiation and progression, is inactivated in the cytoplasm by inhibitory proteins (I&#x003ba;Bs) that have been shown to exert tumor-suppressor activity. Therefore, using The Cancer Genome Atlas copy number alteration and RNA-Seq data from 398 patients, we evaluated the association between the expression and dosage of <italic>NFKBIA</italic>, which encodes I&#x003ba;B&#x003b1;, and the overall malignancy of LGGs. Deletion and low expression of <italic>NFKBIA</italic> were associated with enhanced tumor aggressiveness and poor prognosis in LGGs. Accordingly, the dosage and expression of <italic>NFKBIA</italic> were independent prognostic factors for 5-year survival (dosage: <italic>P</italic>&#x02009;=&#x02009;0.016; expression: <italic>P</italic>&#x02009;=&#x02009;0.002) and 5-year recurrence-free survival (dosage: <italic>P</italic>&#x02009;=&#x02009;0.009; expression: <italic>P</italic>&#x02009;=&#x02009;0.005). Moreover, gene set enrichment analyses and co-expression network analyses indicated a role for <italic>NFKBIA</italic> in the negative regulation of cell proliferation, possibly through the modulation of downstream NF&#x003ba;B activation. Overall, the present findings reveal the prognostic value of <italic>NFKBIA</italic> in LGGs, reinforcing the relevance of NF&#x003ba;B signaling in the development and progression of gliomas.</p></abstract></article-meta></front><body><p>Lower-grade gliomas (LGGs), which are uniformly fatal in young adults, are infiltrative brain tumors that include astrocytomas, oligoastrocytomas and oligodendrogliomas<xref ref-type="bibr" rid="b1">1</xref>. The World Health Organization (WHO) classifies these tumors as grades II-III, primarily based on histological features such as mitotic activity, cellularity, nuclear atypia, microvascular proliferation, and necrosis<xref ref-type="bibr" rid="b2">2</xref>. In addition to traditional morphological histopathology, detailed molecular classification of gliomas also contributes to the WHO grading schemes and will be incorporated into a new integrated diagnosis scheme<xref ref-type="bibr" rid="b3">3</xref><xref ref-type="bibr" rid="b4">4</xref><xref ref-type="bibr" rid="b5">5</xref>. In this sense, molecular pathology will contribute to the stratification of patients in treatment-specific subgroups, which will lead to the development of more personalized and biologically grounded therapies<xref ref-type="bibr" rid="b6">6</xref><xref ref-type="bibr" rid="b7">7</xref>.</p><p>The NF&#x003ba;B family of transcription factors has an essential role in many biological processes, such as inflammation, innate immunity, cell proliferation and apoptosis<xref ref-type="bibr" rid="b8">8</xref>. Additionally, aberrant activation of NF&#x003ba;B is increasingly recognized as a crucial factor in cancer initiation and progression<xref ref-type="bibr" rid="b9">9</xref>. All five members of this protein family (p65, p100/p50, p102/p52, c-Rel and RelB) share a Rel homology domain (RHD), which mediates their dimerization and DNA binding<xref ref-type="bibr" rid="b10">10</xref>. In most quiescent cells, NF&#x003ba;B dimers remain inactive in the cytoplasm, due to their interaction with inhibitory proteins of the I&#x003ba;B family. The I&#x003ba;Bs are characterized by ankyrin repeats, which interact with the RHDs of NF&#x003ba;B proteins, thereby making them transcriptionally inactive<xref ref-type="bibr" rid="b11">11</xref>. The canonical NF&#x003ba;B pathway is typically triggered by pro-inflammatory cytokines and genotoxic stress, leading to the phosphorylation of I&#x003ba;B&#x003b1; and release of NF&#x003ba;B dimers, mainly p50:p65. NF&#x003ba;B can then translocate to the nucleus and activate the expression of target genes involved in the control of inflammation, cell proliferation, apoptosis, migration and angiogenesis<xref ref-type="bibr" rid="b12">12</xref>.</p><p>NF&#x003ba;B activity in gliomas is significantly higher than in normal brain tissues and phospho-I&#x003ba;B&#x003b1; protein levels have been shown to negatively correlate with tumor grade<xref ref-type="bibr" rid="b13">13</xref><xref ref-type="bibr" rid="b14">14</xref><xref ref-type="bibr" rid="b15">15</xref>. Additionally, recent studies have revealed that <italic>NFKBIA</italic>, which encodes I&#x003ba;B&#x003b1;, is deleted in approximately 25% of grade IV gliomas (glioblastomas), the most aggressive primary brain tumors<xref ref-type="bibr" rid="b16">16</xref>. Interestingly, after restoring <italic>NFKBIA</italic> expression in cells cultured from tumors harboring an <italic>NFKBIA</italic> deletion, the malignant phenotype was attenuated and an increase in chemotherapy sensitivity was observed. More importantly, patients with tumors harboring a deletion or low expression of <italic>NFKBIA</italic> demonstrated decreased survival<xref ref-type="bibr" rid="b16">16</xref>. Accordingly, treatment with nanoparticles loaded with recombinant I&#x003ba;B&#x003b1; and curcumin, a natural polyphenol that inhibits the phosphorylation of I&#x003ba;B&#x003b1;, has been shown to decrease the expression of NF&#x003ba;B target genes such as <italic>CCND1, CCNE1, BCL2L1</italic> and <italic>COX2</italic>, thereby inducing apoptotic cell death in a glioblastoma cell line<xref ref-type="bibr" rid="b17">17</xref>.</p><p>Given the potential role of <italic>NFKBIA</italic> in glioblastoma development and progression<xref ref-type="bibr" rid="b15">15</xref><xref ref-type="bibr" rid="b16">16</xref><xref ref-type="bibr" rid="b17">17</xref>, we aimed to investigate, in LGGs, the impact of <italic>NFKBIA</italic> dosage and expression on patient survival, overall malignancy and the downstream activation of NF&#x003ba;B.</p><sec disp-level="1"><title>Results</title><sec disp-level="2"><title><italic>NFKBIA</italic> deletion frequency and mRNA expression</title><p><italic>NFKBIA</italic> deletion was observed in approximately 7% of LGGs from The Cancer Genome Atlas (TCGA) cohort. The deletion was more common in grade III than in grade II gliomas (<xref ref-type="fig" rid="f1">Fig. 1</xref>, <xref ref-type="table" rid="t1">Table 1</xref>), regardless of histologic subtype (<xref ref-type="fig" rid="f1">Fig. 1</xref>). Interestingly, grade III astrocytomas, the most aggressive type of LGG, showed the highest frequency of <italic>NFKBIA</italic> deletion (16.84%, <xref ref-type="fig" rid="f1">Fig. 1a</xref>). Deletions were associated with reduced <italic>NFKBIA</italic> mRNA expression (<xref ref-type="fig" rid="f2">Fig. 2</xref>). Accordingly, grade III gliomas expressed significantly lower levels of <italic>NFKBIA</italic> mRNA compared to grade II gliomas. (<xref ref-type="fig" rid="f2">Fig. 2</xref>, <xref ref-type="table" rid="t2">Table 2</xref>). Patients with LGGs harboring a deletion of <italic>NFKBIA</italic> were significantly older than those with a normal dosage (<xref ref-type="table" rid="t1">Table 1</xref>).</p></sec><sec disp-level="2"><title>Impact of <italic>NFKBIA</italic> dosage and mRNA expression on patient survival</title><p>When we performed univariate analyses of patient survival using Kaplan-Meier curves and Cox univariate regression models, we found that the dosage and expression of <italic>NFKBIA</italic> were significant prognostic factors in LGGs (<xref ref-type="fig" rid="f3">Fig. 3</xref> and <xref ref-type="table" rid="t3">Table 3</xref>). Both deletion and low expression of <italic>NFKBIA</italic> were associated with poor 5-year survival (dosage: HR&#x02009;=&#x02009;6.54, <italic>P</italic>&#x02009;&#x0003c;&#x02009;0.001; expression: HR&#x02009;=&#x02009;0.47, <italic>P</italic>&#x02009;&#x0003c;&#x02009;0.001, <xref ref-type="table" rid="t3">Table 3</xref>) and 5-year recurrence-free survival (RFS; dosage: HR&#x02009;=&#x02009;3.65, <italic>P</italic>&#x02009;=&#x02009;0.001; expression: HR&#x02009;=&#x02009;0.58, <italic>P</italic>&#x02009;=&#x02009;0.001; <xref ref-type="table" rid="t3">Table 3</xref>). To control for possible confounding factors, we also used a multivariate approach, the Cox multivariate regression model, which allowed us to evaluate survival considering multiple variables simultaneously. After adjusting for age, gender, histological subtype and tumor grade, the dosage and expression of <italic>NFKBIA</italic> remained significant prognostic factors for both 5-year survival (dosage: HR&#x02009;=&#x02009;2.15, <italic>P</italic>&#x02009;=&#x02009;0.016; expression: HR&#x02009;=&#x02009;0.54, <italic>P</italic>&#x02009;=&#x02009;0.002; <xref ref-type="table" rid="t4">Tables 4</xref> and <xref ref-type="table" rid="t5">5</xref>) and 5-year RFS (dosage: HR&#x02009;=&#x02009;3.11 <italic>P</italic>&#x02009;=&#x02009;0.009; expression: HR&#x02009;=&#x02009;0.61, <italic>P</italic>&#x02009;=&#x02009;0.005; <xref ref-type="table" rid="t4">Tables 4</xref> and <xref ref-type="table" rid="t5">5</xref>). Notably, in the 5-year RFS analyses no other variable was independently associated with prognosis (<xref ref-type="table" rid="t4">Tables 4</xref> and <xref ref-type="table" rid="t5">5</xref>).</p></sec><sec disp-level="2"><title>Effects of <italic>NFKBIA</italic> dosage and mRNA expression on KEGG biological pathways</title><p>To evaluate the biological relevance of <italic>NFKBIA</italic> dosage and expression in LGGs, we performed gene set enrichment analysis (GSEA) using genes ranked according to i) their differential expression in tumors with <italic>NFKBIA</italic> deletion or ii) their Pearson&#x02019;s correlation with the expression of <italic>NFKBIA.</italic> Among KEGG pathways overexpressed in tumors harboring a deletion of <italic>NFKBIA</italic>, 32 were significantly enriched (<italic>P</italic>&#x02009;&#x0003c;&#x02009;0.05 corrected by false discovery rate, FDR; <xref ref-type="supplementary-material" rid="S1">Supplementary Table S1</xref>). On the other hand, among KEGG pathways negatively correlated with the expression of <italic>NFKBIA</italic>, 10 were significantly enriched (<italic>P</italic>&#x02009;&#x0003c;&#x02009;0.05 corrected by FDR; <xref ref-type="supplementary-material" rid="S1">Supplementary Table S2</xref>). Interestingly, all three pathways significantly enriched in both analyses, namely &#x0201c;cell cycle,&#x0201d; &#x0201c;DNA replication&#x0201d; and &#x0201c;mismatch repair,&#x0201d; are implicated in the process of cell proliferation (<xref ref-type="fig" rid="f4">Fig. 4</xref>).</p></sec><sec disp-level="2"><title>Co-expression analysis of NF&#x003ba;B target genes</title><p>Given that I&#x003ba;B&#x003b1; proteins inhibit the transcriptional activity of p50:p65 NF&#x003ba;B dimers, we sought to investigate if the anti-proliferative role of <italic>NFKBIA,</italic> indicated by the GSEA, was associated with changes in the expression pattern of NF&#x003ba;B target genes. As such, we performed co-expression network analyses using NF&#x003ba;B target genes involved in the positive control of cell proliferation, such as <italic>CCND1, MYC, IL6</italic> and <italic>EGFR</italic>. Interestingly, both deletion and low expression of <italic>NFKBIA</italic> significantly affected the network&#x02019;s spectral distribution (dosage: <italic>P&#x02009;=&#x02009;</italic>0.036; expression: <italic>P</italic>&#x02009;=&#x02009;0.004; <xref ref-type="fig" rid="f5">Fig. 5</xref>), showing that pro-proliferation NF&#x003ba;B target genes were differentially co-expressed between phenotypes (deleted vs. normal and high vs. low; <xref ref-type="fig" rid="f5">Fig. 5</xref>).</p></sec></sec><sec disp-level="1"><title>Discussion</title><p>Previous studies have suggested a correlation between the levels of phospho-I&#x003ba;B&#x003b1; and the grade of gliomas<xref ref-type="bibr" rid="b15">15</xref>; however, to the best of our knowledge, there is no available data assessing the biological and clinical implications of <italic>NFKBIA</italic> dosage and expression in LGGs. Thus, the present findings demonstrate that deletion and low expression of <italic>NFKBIA</italic> are associated with enhanced tumor aggressiveness and poor prognosis in LGGs. Moreover, our data indicate a role for <italic>NFKBIA</italic> in the negative control of cell proliferation, possibly through inhibition of NF&#x003ba;B transcriptional activity.</p><p>The NF&#x003ba;B signal transduction cascade is a multi-component pathway that ultimately controls the expression of genes involved in multiple biological processes<xref ref-type="bibr" rid="b11">11</xref>. The effect of upstream components of the pathway on the activity of NF&#x003ba;B usually determines the expression pattern of target genes<xref ref-type="bibr" rid="b18">18</xref><xref ref-type="bibr" rid="b19">19</xref>. The dysregulation of the NF&#x003ba;B pathway at different levels, either by mutations, epigenetic mechanisms or pharmacological means, is involved in many human diseases, especially chronic inflammation, immunodeficiency and cancer<xref ref-type="bibr" rid="b20">20</xref><xref ref-type="bibr" rid="b21">21</xref><xref ref-type="bibr" rid="b22">22</xref><xref ref-type="bibr" rid="b23">23</xref>. Notably, NF&#x003ba;B is aberrantly activated in tumor cells; however, the mechanisms of activation appear to be complex and vary in different tumor types<xref ref-type="bibr" rid="b9">9</xref><xref ref-type="bibr" rid="b12">12</xref>. Given that the modulation of NF&#x003ba;B activity has an important role in the prevention and management of cancer, careful evaluation of its complex regulation in different tumors is essential<xref ref-type="bibr" rid="b24">24</xref><xref ref-type="bibr" rid="b25">25</xref>.</p><p>In this study, we demonstrate that <italic>NFKBIA</italic>, which encodes I&#x003ba;B&#x003b1;, a critical negative regulator of NF&#x003ba;B canonical activation, is heterozygously deleted in approximately 7% of LGGs. Additionally, grade III tumors presented a higher frequency of <italic>NFKBIA</italic> deletion, combined with reduced mRNA expression, suggesting an association between <italic>NFKBIA</italic> and overall glioma malignancy. More importantly, the dosage and expression of <italic>NFKBIA</italic> were revealed as grade- and histological subtype-independent prognostic factors for both 5-year survival and 5-year RFS. In both cases, the deletion and low expression of <italic>NFKBIA</italic> were associated with poor prognosis, corroborating the idea that I&#x003ba;B proteins demonstrate tumor suppressor functions<xref ref-type="bibr" rid="b23">23</xref><xref ref-type="bibr" rid="b26">26</xref>.</p><p>When released from I&#x003ba;B&#x003b1; proteins, p50:p65 NF&#x003ba;B dimers can promote cell proliferation by regulating the mRNA expression of cell cycle machinery genes, inflammatory cytokines and growth factors<xref ref-type="bibr" rid="b27">27</xref><xref ref-type="bibr" rid="b28">28</xref><xref ref-type="bibr" rid="b29">29</xref><xref ref-type="bibr" rid="b30">30</xref>. Accordingly, our data indicate that <italic>NFKBIA</italic> has a role in the negative control of cell proliferation, changing the co-expression pattern of NF&#x003ba;B target genes. In this sense, GSEA revealed that the expression of many genes involved in cell cycle progression was increased in tumors with <italic>NFKBIA</italic> deletion and negatively correlated with the expression of <italic>NFKBIA.</italic> Moreover, co-expression network analyses suggested that deletions and low expression of <italic>NFKBIA</italic> could promote cell proliferation possibly by interfering with the expression pattern of NF&#x003ba;B target genes. Nevertheless, further studies are needed to better understand the mechanistic implications of deletions and low expression of <italic>NFKBIA</italic> in the control of NF&#x003ba;B signaling in LGGs. In particular, it would be relevant to determine which NF&#x003ba;B dimers are more frequently activated in the absence of <italic>NFKBIA</italic>, and if this aberrant activation could contribute to the transcription of pro-tumoral genes and, consequently, to the acquisition of a more malignant phenotype <italic>in vitro</italic> and <italic>in vivo</italic>.</p><p>The characterization of molecular markers/profiles of LGGs associated with poor outcomes can lay the biological groundwork for the development of rationally designed targeted therapies to improve patient survival. In this sense, despite the limitations intrinsic to our data, the present findings support a role for <italic>NFKBIA</italic> in the control of LGG malignancy, reinforcing the relevance of NF&#x003ba;B signaling in the development and progression of gliomas<xref ref-type="bibr" rid="b31">31</xref>. Thus, therapies that stabilize NF&#x003ba;B-I&#x003ba;B&#x003b1; interactions in the cytoplasm might effectively restrain oncogenic signaling, especially in tumors presenting a deletion or low expression of <italic>NFKBIA</italic>.</p></sec><sec disp-level="1"><title>Materials and Methods</title><sec disp-level="2"><title>TCGA data</title><p>We obtained clinical, RNA-Seq (V2), and Copy Number Alteration (CNA) level 3 data from LGGs in TCGA<xref ref-type="bibr" rid="b32">32</xref> using the Cancer Genomics Hub portal<xref ref-type="bibr" rid="b33">33</xref> and the TCGA-Assembler package<xref ref-type="bibr" rid="b34">34</xref>. Datasets comprised clinical data from 530 patients, CNA data from 512 patients and RNA-Seq data from 528 patients, the intersection of which consisted of 512 cases for which all three types of data were present. Patients with missing histological grade were excluded from this study, leading to a set of 398 cases, which were used in all the analyses. All data pre-processing was performed using the R software package (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://www.r-project.org">http://www.r-project.org</ext-link>).</p><p>CNA detection was performed using the Affymetrix (Santa Clara, USA) <italic>Genome-Wide Human SNP Array 6.0</italic> platform, with approximately 1.8 million genetic markers divided into 900,00 SNP and 906,600 CNA detection probes, spread across the human genome. Data processing was performed using GenePattern&#x02019;s Affymetrix SNP6 Copy Number Inference pipeline. Normalization of CNA values was performed using the circular binary segmentation algorithm<xref ref-type="bibr" rid="b35">35</xref>. The magnitude of <italic>NFKBIA</italic> CNAs was measured using a simplified version of a previous classification scheme, where tumors were labeled as &#x0201c;complete deletion&#x0201d; when the log<sub>2</sub> of the normalized CNA value was less than or equal to &#x02212;1: &#x0201c;deletion,&#x0201d; when the value was between &#x02212;1 and &#x02212;0.2, or &#x0201c;normal,&#x0201d; when the value was between &#x02212;0.2 and 0.2<xref ref-type="bibr" rid="b36">36</xref>.</p><p>RNA sequencing was performed using the <italic>Illumina HiSeq 2000</italic> platform and data processing was performed through the second analysis pipeline (RNASeqV2), using MapSplice<xref ref-type="bibr" rid="b37">37</xref> and RSEM<xref ref-type="bibr" rid="b38">38</xref> for gene mapping and gene expression quantification, respectively. Tumors were dichotomized, as &#x0201c;low&#x0201d; or &#x0201c;high,&#x0201d; according to <italic>NFKBIA</italic> expression using the median expression value as a cutoff.</p></sec><sec disp-level="2"><title>GSEA</title><p>All genes from TCGA RNAseq dataset were pre-ranked according to: i) their differential expression (fold change) comparing tumors with normal and deleted <italic>NFKBIA</italic> dosages (median<sub>deleted</sub>/median<sub>normal</sub>), or ii) Pearson&#x02019;s correlation between their expression and the expression of <italic>NFKBIA</italic>. GSEA was performed using GSEA v4.0<xref ref-type="bibr" rid="b39">39</xref> and KEGG pathways<xref ref-type="bibr" rid="b40">40</xref>. Enrichment scores (ES) were calculated based on a Kolmogorov&#x02013;Smirnov statistic and tested for significance using 1,000 permutations. ES were further normalized (NES) to account for the size of each gene set. <italic>P</italic>-values corresponding to each NES were corrected for multiple comparisons by the FDR procedure<xref ref-type="bibr" rid="b39">39</xref>. Adjusted <italic>P</italic>-values&#x02009;&#x0003c;&#x02009;0.05 were considered statistically significant.</p></sec><sec disp-level="2"><title>Co-expression network analysis</title><p>To construct co-expression networks, we selected NF&#x003ba;B target genes involved in the positive control of cell proliferation, namely: <italic>CCND1, CCND2, CCND3, CCNE1, CDK2, MYC, TNF, IL1B, IL6, EGFR, MDK, PTGS2</italic>. In these undirected weighted co-expression networks, genes are nodes, while edges represent the pairwise correlations between gene expressions. Edge weights correspond to the Spearman&#x02019;s correlation coefficient between gene pairs. Networks were visualized using the igraph package<xref ref-type="bibr" rid="b41">41</xref> in R (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://www.r-project.org">http://www.r-project.org</ext-link>).</p><p>We used CoGA software<xref ref-type="bibr" rid="b42">42</xref> to compare networks built according to <italic>NFKBIA</italic> dosage (normal vs. deleted) and expression (high vs. low). CoGA identifies structural differences between networks by using graph spectral distribution. The spectrum of a graph is the set of eigenvalues of its adjacency matrix. The spectrum is a general way to describe the structure of a network and can be used to determine if two networks were generated by the same model<xref ref-type="bibr" rid="b43">43</xref>. We considered that two networks were significantly different by rejecting the null hypothesis of the equality test with an adjusted <italic>P</italic>-value (corrected for multiple comparisons by the FDR procedure) threshold of 5%.</p></sec><sec disp-level="2"><title>Statistical Analysis</title><p>Two-group comparisons were analyzed using two-sided Student&#x02019;s t tests. The chi-square test was used to access the association between various categorical clinicopathological characteristics and <italic>NFKBIA</italic> dosage (normal vs. deleted) and expression (high vs. low). We evaluated the impact of <italic>NFKBIA</italic> dosage and expression on both patient overall survival and RFS using Kaplan-Meier curves and the log-rank test<xref ref-type="bibr" rid="b44">44</xref> in addition to uni- and multivariate Cox proportional hazard models<xref ref-type="bibr" rid="b45">45</xref>. HRs, including 95% confidence intervals, were calculated. The survival time was right-censored by 5 years. Statistical analyses were performed with GraphPad Prism 6 and R (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://www.r-project.org">http://www.r-project.org</ext-link>). <italic>P</italic>-values&#x02009;&#x0003c;&#x02009;0.05 were considered statistically significant.</p></sec></sec><sec disp-level="1"><title>Additional Information</title><p><bold>How to cite this article</bold>: Kinker, G. S. <italic>et al</italic>. Deletion and low expression of <italic>NFKBIA</italic> are associated with poor prognosis in lower-grade glioma patients. <italic>Sci. Rep.</italic>
<bold>6</bold>, 24160; doi: 10.1038/srep24160 (2016).</p></sec><sec sec-type="supplementary-material" id="S1"><title>Supplementary Material</title><supplementary-material id="d33e24" content-type="local-data"><caption><title>Supplementary Information</title></caption><media xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="srep24160-s1.pdf"/></supplementary-material></sec></body><back><ack><p>G.S.K was supported by fellowships from CNPq (162670/2014-1) and the S&#x000e3;o Paulo Research Foundation (FAPESP, 2014/27287-0), A.M.T was supported by a fellowship from FAPESP (2015/01507-7) and V.J.C was supported by a fellowship from the Coordination for the Improvement of Higher Education Personnel (CAPES, Brazilian Ministry of Education). A.F. received financial support from FAPESP (2013/03447-6, 2014/09576-5, and 2015/01587-0), the Brazilian National Council for Research in Science and Technology (CNPq, 304020/2013-3 and 473063/2013-1) and the eScience Research Network (Research Support Center, University of S&#x000e3;o Paulo).</p></ack><ref-list><ref id="b1"><mixed-citation publication-type="journal"><name><surname>Ricard</surname><given-names>D.</given-names></name>
<etal/>. <article-title>Primary brain tumours in adults</article-title>. <source>Lancet</source>
<volume>379</volume>, <fpage>1984</fpage>&#x02013;<lpage>1996</lpage> (<year>2012</year>).<pub-id pub-id-type="pmid">22510398</pub-id></mixed-citation></ref><ref id="b2"><mixed-citation publication-type="journal"><name><surname>Louis</surname><given-names>D. N.</given-names></name>
<etal/>.<article-title> The 2007 WHO classification of tumours of the central nervous system</article-title>. <source>Acta Neuropathol.</source>
<volume>114</volume>, <fpage>97</fpage>&#x02013;<lpage>109</lpage> (<year>2007</year>).<pub-id pub-id-type="pmid">17618441</pub-id></mixed-citation></ref><ref id="b3"><mixed-citation publication-type="journal"><name><surname>Louis</surname><given-names>D. N.</given-names></name>
<etal/>. <article-title>International Society Of Neuropathology&#x02014;Haarlem consensus guidelines for nervous system tumor classification and grading</article-title>. <source>Brain Pathol.</source>
<volume>24</volume>, <fpage>429</fpage>&#x02013;<lpage>435</lpage> (<year>2014</year>).<pub-id pub-id-type="pmid">24990071</pub-id></mixed-citation></ref><ref id="b4"><mixed-citation publication-type="journal"><name><surname>Eckel-Passow</surname><given-names>J. E.</given-names></name>
<article-title>Glioma groups based on 1p/19q, IDH, and TERT promoter mutations in tumors</article-title>. <source>N. Engl. J. Med.</source>
<volume>372</volume>, <fpage>2499</fpage>&#x02013;<lpage>2508</lpage> (<year>2015</year>).<pub-id pub-id-type="pmid">26061753</pub-id></mixed-citation></ref><ref id="b5"><mixed-citation publication-type="journal"><name><surname>Weller</surname><given-names>M.</given-names></name>
<etal/>. <article-title>Molecular classification of diffuse cerebral WHO grade II/III gliomas using genome-and transcriptome-wide profiling improves stratification of prognostically distinct patient groups</article-title>. <source>Acta Neuropathol.</source>
<volume>129</volume>, <fpage>679</fpage>&#x02013;<lpage>693</lpage> (<year>2015</year>).<pub-id pub-id-type="pmid">25783747</pub-id></mixed-citation></ref><ref id="b6"><mixed-citation publication-type="journal"><name><surname>Vitucci</surname><given-names>M.</given-names></name>, <name><surname>Hayes</surname><given-names>D. N.</given-names></name> &#x00026; <name><surname>Miller</surname><given-names>C. R.</given-names></name>
<article-title>Gene expression profiling of gliomas: merging genomic and histopathological classification for personalised therapy</article-title>. <source>Br. J. Cancer</source>
<volume>104</volume>, <fpage>545</fpage>&#x02013;<lpage>553</lpage> (<year>2011</year>).<pub-id pub-id-type="pmid">21119666</pub-id></mixed-citation></ref><ref id="b7"><mixed-citation publication-type="journal"><name><surname>Weller</surname><given-names>M.</given-names></name>
<etal/>. <article-title>MGMT promoter methylation in malignant gliomas: ready for personalized medicine?</article-title>
<source>Nat. Rev. Neurol.</source>
<volume>6</volume>, <fpage>39</fpage>&#x02013;<lpage>51</lpage> (<year>2010</year>).<pub-id pub-id-type="pmid">19997073</pub-id></mixed-citation></ref><ref id="b8"><mixed-citation publication-type="journal"><name><surname>Hayden</surname><given-names>M. S.</given-names></name> &#x00026; <name><surname>Ghosh</surname><given-names>S. S.</given-names></name>
<article-title>NF-&#x003ba;B, the first quarter-century: remarkable progress and outstanding questions</article-title>. <source>Genes Dev.</source>
<volume>26</volume>, <fpage>203</fpage>&#x02013;<lpage>234</lpage> (<year>2012</year>).<pub-id pub-id-type="pmid">22302935</pub-id></mixed-citation></ref><ref id="b9"><mixed-citation publication-type="journal"><name><surname>Karin</surname><given-names>M.</given-names></name>, <name><surname>Cao</surname><given-names>Y.</given-names></name>, <name><surname>Greten</surname><given-names>F. R.</given-names></name> &#x00026; <name><surname>Li</surname><given-names>Z. M.</given-names></name>
<article-title>NF-&#x003ba;B in cancer: from innocent bystander to major culprit</article-title>. <source>Nat. Rev. Cancer</source>
<volume>2</volume>, <fpage>301</fpage>&#x02013;<lpage>310</lpage> (<year>2002</year>).<pub-id pub-id-type="pmid">12001991</pub-id></mixed-citation></ref><ref id="b10"><mixed-citation publication-type="journal"><name><surname>Ghosh</surname><given-names>S.</given-names></name>, <name><surname>May</surname><given-names>M. J.</given-names></name> &#x00026; <name><surname>Kopp</surname><given-names>E. B.</given-names></name>
<article-title>NF-kappa B. and Rel proteins: evolutionarily conserved mediators of immune responses</article-title>. <source>Annu. Rev. of Immunol</source>. <volume>16</volume>, <fpage>225</fpage>&#x02013;<lpage>60</lpage> (<year>1998</year>).<pub-id pub-id-type="pmid">9597130</pub-id></mixed-citation></ref><ref id="b11"><mixed-citation publication-type="journal"><name><surname>Gilmore</surname><given-names>T. D.</given-names></name>
<article-title>Introduction to NF-&#x003ba;B: players, pathways, perspectives</article-title>. <source>Oncogene</source>
<volume>25</volume>, <fpage>6680</fpage>&#x02013;<lpage>6684</lpage> (<year>2006</year>).<pub-id pub-id-type="pmid">17072321</pub-id></mixed-citation></ref><ref id="b12"><mixed-citation publication-type="journal"><name><surname>Hoesel</surname><given-names>B.</given-names></name> &#x00026; <name><surname>Schmid</surname><given-names>J. A.</given-names></name>
<article-title>The complexity of NF-&#x003ba;B signaling in inflammation and cancer</article-title>. <source>Mol. Cancer</source>
<volume>12</volume>, <fpage>1</fpage>&#x02013;<lpage>15</lpage> (<year>2013</year>).<pub-id pub-id-type="pmid">23286373</pub-id></mixed-citation></ref><ref id="b13"><mixed-citation publication-type="journal"><name><surname>Angileri</surname><given-names>F. F.</given-names></name>
<etal/>. <article-title>Nuclear factor&#x02010;&#x003ba;B activation and differential expression of survivin and Bcl&#x02010;2 in human grade 2&#x02013;4 astrocytomas</article-title>. <source>Cancer</source>
<volume>112</volume>, <fpage>2258</fpage>&#x02013;<lpage>2266</lpage> (<year>2008</year>).<pub-id pub-id-type="pmid">18327814</pub-id></mixed-citation></ref><ref id="b14"><mixed-citation publication-type="journal"><name><surname>Wang</surname><given-names>H.</given-names></name>, <name><surname>Zhang</surname><given-names>W.</given-names></name>, <name><surname>Huang</surname><given-names>H. J.</given-names></name>, <name><surname>Liao</surname><given-names>W. S.</given-names></name> &#x00026; <name><surname>Fuller</surname><given-names>G. N.</given-names></name>
<article-title>Analysis of the activation status of Akt, NF- &#x003ba;B, and Stat3 in human diffuse gliomas</article-title>. <source>Lab. Invest.</source>
<volume>84</volume>, <fpage>941</fpage>&#x02013;<lpage>951</lpage> (<year>2004</year>).<pub-id pub-id-type="pmid">15184909</pub-id></mixed-citation></ref><ref id="b15"><mixed-citation publication-type="journal"><name><surname>Korkolopoulou</surname><given-names>P.</given-names></name>
<etal/>. <article-title>Expression of nuclear factor-&#x003ba;B in human astrocytomas: relation to pI&#x003ba;Ba, vascular endothelial growth factor, Cox-2, microvascular characteristics, and survival</article-title>. <source>Hum. Pathol.</source>
<volume>39</volume>, <fpage>1143</fpage>&#x02013;<lpage>1152</lpage> (<year>2008</year>).<pub-id pub-id-type="pmid">18495209</pub-id></mixed-citation></ref><ref id="b16"><mixed-citation publication-type="journal"><name><surname>Bredel</surname><given-names>M.</given-names></name>
<etal/>., <article-title><italic>NFKBIA</italic> deletion in glioblastomas</article-title>. <source>N. Engl. J. Med.</source>
<volume>364</volume>, <fpage>627</fpage>&#x02013;<lpage>637</lpage> (<year>2011</year>).<pub-id pub-id-type="pmid">21175304</pub-id></mixed-citation></ref><ref id="b17"><mixed-citation publication-type="journal"><name><surname>Banerjee</surname><given-names>S.</given-names></name>, <name><surname>Sahoo</surname><given-names>A. K.</given-names></name>, <name><surname>Chattopadhyay</surname><given-names>A.</given-names></name> &#x00026; <name><surname>Ghosh</surname><given-names>S. S.</given-names></name>
<article-title>Recombinant I&#x003ba;B&#x003b1;-loaded curcumin nanoparticles for improved cancer therapeutics</article-title>. <source>Nanotechnology</source>
<volume>25</volume>, <fpage>345102</fpage> (<year>2014</year>).<pub-id pub-id-type="pmid">25091588</pub-id></mixed-citation></ref><ref id="b18"><mixed-citation publication-type="journal"><name><surname>Courtois</surname><given-names>G.</given-names></name> &#x00026; <name><surname>Gilmore</surname><given-names>T. D.</given-names></name>
<article-title>Mutations in the NF-&#x003ba;B signaling pathway: implications for human disease</article-title>. <source>Oncogene</source>
<volume>25</volume>, <fpage>6831</fpage>&#x02013;<lpage>6843</lpage> (<year>2006</year>).<pub-id pub-id-type="pmid">17072331</pub-id></mixed-citation></ref><ref id="b19"><mixed-citation publication-type="journal"><name><surname>Lin</surname><given-names>Y.</given-names></name>, <name><surname>Bai</surname><given-names>L.</given-names></name>, <name><surname>Chen</surname><given-names>W.</given-names></name> &#x00026; <name><surname>Xu</surname><given-names>S.</given-names></name>
<article-title>The NF-&#x003ba;B activation pathways, emerging molecular targets for cancer prevention and therapy</article-title>. <source>Expert Opin. Ther. Targets</source>
<volume>14</volume>, <fpage>45</fpage>&#x02013;<lpage>55</lpage> (<year>2010</year>).<pub-id pub-id-type="pmid">20001209</pub-id></mixed-citation></ref><ref id="b20"><mixed-citation publication-type="journal"><name><surname>Smahi</surname><given-names>A.</given-names></name>
<etal/>. <article-title>Genomic rearrangement in NEMO impairs NF-&#x003ba;B activation and is a cause of incontinentia pigmentim</article-title>. <source>Nature</source>
<volume>405</volume>, <fpage>466</fpage>&#x02013;<lpage>472</lpage> (<year>2000</year>).<pub-id pub-id-type="pmid">10839543</pub-id></mixed-citation></ref><ref id="b21"><mixed-citation publication-type="journal"><name><surname>Courtois</surname><given-names>G.</given-names></name>
<etal/>. <article-title>A hypermorphic I&#x003ba;B&#x003b1; mutation is associated with autosomal dominant anhidrotic ectodermal dysplasia and T cell immunodeficiency</article-title>. <source>J. Clin. Invest.</source>
<volume>112</volume>, <fpage>1108</fpage> (<year>2003</year>).<pub-id pub-id-type="pmid">14523047</pub-id></mixed-citation></ref><ref id="b22"><mixed-citation publication-type="journal"><name><surname>Barth</surname><given-names>T. F.</given-names></name>
<etal/>. <article-title>Gains of 2p involving the REL locus correlate with nuclear c-Rel protein accumulation in neoplastic cells of classical Hodgkin lymphoma</article-title>. <source>Blood</source>
<volume>101</volume>, <fpage>3681</fpage>&#x02013;<lpage>3686</lpage> (<year>2003</year>).<pub-id pub-id-type="pmid">12511414</pub-id></mixed-citation></ref><ref id="b23"><mixed-citation publication-type="journal"><name><surname>Cabannes</surname><given-names>E.</given-names></name>, <name><surname>Khan</surname><given-names>G.</given-names></name>, <name><surname>Aillet</surname><given-names>F.</given-names></name>, <name><surname>Jarrett</surname><given-names>R. F.</given-names></name> &#x00026; <name><surname>Hay</surname><given-names>R. T.</given-names></name>
<article-title>Mutations in the IkBa gene in Hodgkin&#x02019;s disease suggest a tumour suppressor role for IkBa</article-title>. <source>Oncogene</source>
<volume>18</volume>, <fpage>3063</fpage>&#x02013;<lpage>3070</lpage> (<year>1999</year>).<pub-id pub-id-type="pmid">10340377</pub-id></mixed-citation></ref><ref id="b24"><mixed-citation publication-type="journal"><name><surname>Atkinson</surname><given-names>G. P.</given-names></name>, <name><surname>Nozell</surname><given-names>S. E.</given-names></name> &#x00026; <name><surname>Benveniste</surname><given-names>E. T. N.</given-names></name>
<article-title>NF-&#x003ba;B and STAT3 signaling in glioma: targets for future therapies</article-title>. <source>Expert Rev. Neurother</source>. <volume>10</volume>, <fpage>575</fpage>&#x02013;<lpage>86</lpage> (<year>2010</year>).<pub-id pub-id-type="pmid">20367209</pub-id></mixed-citation></ref><ref id="b25"><mixed-citation publication-type="journal"><name><surname>Baud</surname><given-names>V.</given-names></name> &#x00026; <name><surname>Karin</surname><given-names>M.</given-names></name>
<article-title>Is NF-&#x003ba;B a good target for cancer therapy&#x02009;?&#x02009;Hopes and pitfalls</article-title>. <source>Nat. Rev. Drug Discov.</source>
<volume>8</volume>, <fpage>33</fpage>&#x02013;<lpage>40</lpage> (<year>2009</year>).<pub-id pub-id-type="pmid">19116625</pub-id></mixed-citation></ref><ref id="b26"><mixed-citation publication-type="journal"><name><surname>Jungnickel</surname><given-names>B.</given-names></name>
<etal/>. <article-title>Clonal deleterious mutations in the I&#x003ba;B&#x003b1; gene in the malignant cells in Hodgkin&#x02019;s lymphoma</article-title>. <source>J. Exp. Med.</source>
<volume>191</volume>, <fpage>395</fpage>&#x02013;<lpage>402</lpage> (<year>2000</year>).<pub-id pub-id-type="pmid">10637284</pub-id></mixed-citation></ref><ref id="b27"><mixed-citation publication-type="journal"><name><surname>Hinz</surname><given-names>M.</given-names></name>
<etal/>. <article-title>NF-kappaB function in growth control: regulation of cyclin D1 expression and G0/G1-to-S-phase transition</article-title>. <source>Mol. Cell. Biol.</source>
<volume>19</volume>, <fpage>2690</fpage>&#x02013;<lpage>2698</lpage> (<year>1999</year>).<pub-id pub-id-type="pmid">10082535</pub-id></mixed-citation></ref><ref id="b28"><mixed-citation publication-type="journal"><name><surname>Hsia</surname><given-names>C. Y.</given-names></name>, <name><surname>Cheng</surname><given-names>S.</given-names></name>, <name><surname>Owyang</surname><given-names>A. M.</given-names></name>, <name><surname>Dowdy</surname><given-names>S. F.</given-names></name> &#x00026; <name><surname>Liou</surname><given-names>H. C.</given-names></name>
<article-title>c-Rel regulation of the cell cycle in primary mouse B lymphocytes</article-title>. <source>Int. Immunol.</source>
<volume>14</volume>, <fpage>905</fpage>&#x02013;<lpage>916</lpage> (<year>2002</year>).<pub-id pub-id-type="pmid">12147627</pub-id></mixed-citation></ref><ref id="b29"><mixed-citation publication-type="journal"><name><surname>McFarland</surname><given-names>B. C.</given-names></name>
<etal/>. <article-title>NF-kappaB-induced IL-6 ensures STAT3 activation and tumor aggressiveness in glioblastoma</article-title>. <source>PLoS One</source>
<volume>8</volume>, <fpage>e78728</fpage> (<year>2013</year>).<pub-id pub-id-type="pmid">24244348</pub-id></mixed-citation></ref><ref id="b30"><mixed-citation publication-type="journal"><name><surname>Bonavia</surname><given-names>R.</given-names></name>
<etal/>. <article-title>EGFRvIII promotes glioma angiogenesis and growth through the NF-kappaB, interleukin-8 pathway</article-title>. <source>Oncogene</source>
<volume>31</volume>, <fpage>4054</fpage>&#x02013;<lpage>66</lpage> (<year>2012</year>).<pub-id pub-id-type="pmid">22139077</pub-id></mixed-citation></ref><ref id="b31"><mixed-citation publication-type="journal"><name><surname>Puliyappadamba</surname><given-names>V. T.</given-names></name>, <name><surname>Hatanpaa</surname><given-names>K. J.</given-names></name>, <name><surname>Chakraborty</surname><given-names>S.</given-names></name> &#x00026; <name><surname>Habib</surname><given-names>A. A.</given-names></name>
<article-title>The role of NF-&#x003ba;B in the pathogenesis of glioma</article-title>. <source>Mol. Cell. Oncol</source>
<volume>1</volume>, <fpage>e963478</fpage> (<year>2014</year>).</mixed-citation></ref><ref id="b32"><mixed-citation publication-type="journal"><name><surname>Tomczak</surname><given-names>K.</given-names></name>, <name><surname>Czerwi&#x00144;ska</surname><given-names>P.</given-names></name> &#x00026; <name><surname>Wiznerowicz</surname><given-names>M.</given-names></name>
<article-title>The Cancer Genome Atlas (TCGA): an immeasurable source of knowledge</article-title>. <source>Contemp. Oncol.</source>
<volume>19</volume>, <fpage>A68</fpage>&#x02013;<lpage>77</lpage> (<year>2015</year>).</mixed-citation></ref><ref id="b33"><mixed-citation publication-type="journal"><name><surname>Wilks</surname><given-names>C.</given-names></name>
<etal/>. <article-title>The Cancer Genomics Hub (CGHub): overcoming cancer through the power of torrential data</article-title>. <source>Database</source>
<volume>2014</volume>, <fpage>bau093</fpage> (<year>2014</year>).<pub-id pub-id-type="pmid">25267794</pub-id></mixed-citation></ref><ref id="b34"><mixed-citation publication-type="journal"><name><surname>Zhu</surname><given-names>Y.</given-names></name>, <name><surname>Qiu</surname><given-names>P.</given-names></name> &#x00026; <name><surname>Ji</surname><given-names>Y.</given-names></name>
<article-title>TCGA-Assembler: open-source software for retrieving and processing TCGA data</article-title>. <source>Nat. Methods</source>
<volume>11</volume>, <fpage>599</fpage>&#x02013;<lpage>600</lpage> (<year>2014</year>).<pub-id pub-id-type="pmid">24874569</pub-id></mixed-citation></ref><ref id="b35"><mixed-citation publication-type="journal"><name><surname>Olshen</surname><given-names>A. B.</given-names></name>, <name><surname>Venkatraman</surname><given-names>E. S.</given-names></name>, <name><surname>Lucito</surname><given-names>R.</given-names></name> &#x00026; <name><surname>Wigler</surname><given-names>M.</given-names></name>
<article-title>Circular binary segmentation for the analysis of array based DNA copy number data</article-title>. <source>Biostatistics</source>
<volume>5</volume>, <fpage>557</fpage>&#x02013;<lpage>572</lpage> (<year>2004</year>).<pub-id pub-id-type="pmid">15475419</pub-id></mixed-citation></ref><ref id="b36"><mixed-citation publication-type="journal"><name><surname>Brennan</surname><given-names>C. W.</given-names></name>
<etal/>. <article-title>The somatic genomic landscape of glioblastoma</article-title>. <source>Cell</source>
<volume>155</volume>, <fpage>462</fpage>&#x02013;<lpage>77</lpage> (<year>2013</year>).<pub-id pub-id-type="pmid">24120142</pub-id></mixed-citation></ref><ref id="b37"><mixed-citation publication-type="journal"><name><surname>Wang</surname><given-names>K.</given-names></name>
<etal/>. <article-title>MapSplice: accurate mapping of RNA-Seq reads for splice junction discovery</article-title>. <source>Nucleic Acids Res.</source>
<volume>38</volume>, <fpage>e178</fpage>&#x02013;<lpage>e178</lpage> (<year>2010</year>).<pub-id pub-id-type="pmid">20802226</pub-id></mixed-citation></ref><ref id="b38"><mixed-citation publication-type="journal"><name><surname>Li</surname><given-names>B.</given-names></name> &#x00026; <name><surname>Dewey</surname><given-names>C. N.</given-names></name>
<article-title>RSEM: accurate transcript quantification from RNA-Seq data with or without a reference genome</article-title>. <source>BMC Bioinformatics</source>
<volume>12</volume>, <fpage>323</fpage> (<year>2011</year>).<pub-id pub-id-type="pmid">21816040</pub-id></mixed-citation></ref><ref id="b39"><mixed-citation publication-type="journal"><name><surname>Subramanian</surname><given-names>A.</given-names></name>
<etal/>. <article-title>Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles</article-title>. <source>Proc. Natl. Acad. Sci. USA</source>
<volume>102</volume>, <fpage>15545</fpage>&#x02013;<lpage>15550</lpage> (<year>2005</year>).<pub-id pub-id-type="pmid">16199517</pub-id></mixed-citation></ref><ref id="b40"><mixed-citation publication-type="journal"><name><surname>Ogata</surname><given-names>H.</given-names></name>, <name><surname>Goto</surname><given-names>S.</given-names></name>, <name><surname>Sato</surname><given-names>K.</given-names></name>, <name><surname>Fujibuchi</surname><given-names>W.</given-names></name>, <name><surname>Bono</surname><given-names>H.</given-names></name> &#x00026; <name><surname>Kanehisa</surname><given-names>M.</given-names></name>
<article-title>KEGG: Kyoto encyclopedia of genes and genomes</article-title>. <source>Nucleic Acids Res.</source>
<volume>27</volume>, <fpage>29</fpage>&#x02013;<lpage>34</lpage> (<year>1999</year>).<pub-id pub-id-type="pmid">9847135</pub-id></mixed-citation></ref><ref id="b41"><mixed-citation publication-type="journal"><name><surname>Csardi</surname><given-names>G.</given-names></name> &#x00026; <name><surname>Nepusz</surname><given-names>T.</given-names></name>
<article-title>The igraph software package for complex network research</article-title>. <source>InterJournal, Complex Systems</source>
<volume>1695</volume>, <fpage>1</fpage>&#x02013;<lpage>9</lpage> (<year>2006</year>).</mixed-citation></ref><ref id="b42"><mixed-citation publication-type="journal"><name><surname>de Siqueira Santos</surname><given-names>S.</given-names></name>
<etal/>. <article-title>CoGA: An R Package to Identify Differentially Co-Expressed Gene Sets by Analyzing the Graph Spectra</article-title>. <source>PLoS One</source>
<volume>10</volume>, <fpage>e0135831</fpage> (<year>2015</year>).<pub-id pub-id-type="pmid">26313749</pub-id></mixed-citation></ref><ref id="b43"><mixed-citation publication-type="journal"><name><surname>Takahashi</surname><given-names>D. Y.</given-names></name>, <name><surname>Sato</surname><given-names>J. R.</given-names></name>, <name><surname>Ferreira</surname><given-names>C. E.</given-names></name> &#x00026; <name><surname>Fujita</surname><given-names>A.</given-names></name>
<article-title>Discriminating different classes of biological networks by analyzing the graphs spectra distribution</article-title>. <source>PLoS One</source>
<volume>7</volume>, <fpage>e49949</fpage> (<year>2012</year>).<pub-id pub-id-type="pmid">23284629</pub-id></mixed-citation></ref><ref id="b44"><mixed-citation publication-type="journal"><name><surname>Clark</surname><given-names>T. G.</given-names></name>, <name><surname>Bradburn</surname><given-names>M. J.</given-names></name>, <name><surname>Love</surname><given-names>S. B.</given-names></name> &#x00026; <name><surname>Altman</surname><given-names>D. G.</given-names></name>
<article-title>Survival analysis part I: basic concepts and first analyses</article-title>. <source>Br. J. Cancer</source>
<volume>89</volume>, <fpage>232</fpage> (<year>2003</year>).<pub-id pub-id-type="pmid">12865907</pub-id></mixed-citation></ref><ref id="b45"><mixed-citation publication-type="journal"><name><surname>Bradburn</surname><given-names>M. J.</given-names></name>, <name><surname>Clark</surname><given-names>T. J.</given-names></name>, <name><surname>Love</surname><given-names>S. B.</given-names></name> &#x00026; <name><surname>Altman</surname><given-names>D. G.</given-names></name>
<article-title>Survival analysis part II: multivariate data analysis&#x02013;an introduction to concepts and methods</article-title>. <source>Br. J. Cancer</source>
<volume>89</volume>, <fpage>431</fpage> (<year>2003</year>).<pub-id pub-id-type="pmid">12888808</pub-id></mixed-citation></ref></ref-list><fn-group><fn><p><bold>Author Contributions</bold> G.S.K., A.M.T., V.J.C. and F.P.L. designed the study and performed the analyses. All authors analyzed the data and wrote the manuscript. A.F. critically revised the manuscript for important intellectual content and has given the final approval of the version to be published.</p></fn></fn-group></back><floats-group><fig id="f1"><label>Figure 1</label><caption><title>Proportion of <italic>NFKBIA</italic> deletions in lower-grade gliomas (LGGs).</title><p><italic>NFKBIA</italic> dosage profile in (<bold>a</bold>) all LGGs, (<bold>b</bold>) astrocytomas, (<bold>c</bold>) oligoastrocytomas and (<bold>d</bold>) oligodendrogliomas according to tumor grade. The CNA magnitudes (x&#x02009;=&#x02009;log<sub>2</sub> ratio) were classified using simple thresholds: complete deletion (x&#x02009;&#x02264;&#x02009;&#x02212;1), deletion (&#x02212;1&#x02009;&#x0003c;&#x02009;x&#x02009;&#x02264;&#x02009;&#x02212;0.2), and normal (&#x02212;0.2&#x02009;&#x0003c;&#x02009;x&#x02009;&#x02264;&#x02009;0.2).</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="srep24160-f1"/></fig><fig id="f2"><label>Figure 2</label><caption><title><italic>NFKBIA</italic> expression in lower-grade gliomas (LGGs).</title><p>RNAseq analysis of <italic>NFKBIA</italic> expression according to (<bold>a</bold>) dosage of <italic>NFKBIA</italic> (normal vs. deleted) and (<bold>b</bold>) tumor grade (GII vs. GIII). Gene expression values were estimated using RSEM. The box extends from the 25th to the 75th percentile, the central bold line shows the median, with whiskers being drawn down to the 10th percentile and up to the 90th. Comparisons were performed using the two-sided Student&#x02019;s t test.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="srep24160-f2"/></fig><fig id="f3"><label>Figure 3</label><caption><title>Dosage and expression of <italic>NFKBIA</italic> are prognostic markers in LGGs.</title><p>Kaplan-Meier analysis of 5-year survival and 5-year recurrence-free survival (RFS) according to (<bold>a</bold>) <italic>NFKBIA</italic> dosage (normal vs. deleted) and (<bold>b</bold>) <italic>NFKBIA</italic> expression (high vs. low). Comparisons were performed using the log-rank test.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="srep24160-f3"/></fig><fig id="f4"><label>Figure 4</label><caption><title><italic>NFKBIA</italic> has a role in the negative control of cell proliferation.</title><p>Gene sets involved in the positive control of cell proliferation comprise genes presenting (<bold>a</bold>) increased expression in tumors harboring <italic>NFKBIA</italic> deletions and (<bold>b</bold>) negative correlations with the expression of <italic>NFKBIA</italic>. Normalized enrichment scores (NES) and <italic>P-</italic>values corrected by false discovery rate (FDR) were calculated using GSEA v4.0 and KEGG pathways.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="srep24160-f4"/></fig><fig id="f5"><label>Figure 5</label><caption><title>Deletion and low expression of <italic>NFKBIA</italic> alter the co-expression pattern of pro-proliferation NF&#x003ba;B target genes.</title><p>Undirected and weighted networks were built using (<bold>a</bold>) tumors with normal (left) vs. deleted (right) <italic>NFKBIA</italic> and (<bold>b</bold>) tumors with high (left) vs. low (right) <italic>NFKBIA</italic> expression. Positive correlations are indicated with continuous lines and negative correlations with dashed lines. Edge weights (thicknesses) are proportional to the Spearman&#x02019;s correlation coefficient between gene pairs. Networks were compared using CoGA software and <italic>P</italic>-values corrected by false discovery rate (FDR) are indicated.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="srep24160-f5"/></fig><table-wrap position="float" id="t1"><label>Table 1</label><caption><title>Clinicopathological features according to the dosage of <italic>NFKBIA</italic>.</title></caption><table frame="hsides" rules="groups" border="1"><colgroup><col align="left"/><col align="center"/><col align="center"/><col align="center"/></colgroup><thead valign="bottom"><tr><th rowspan="3" align="left" valign="middle" charoff="50">Variables</th><th colspan="3" align="center" valign="top" charoff="50"><italic>NFKBIA</italic> dosage<hr/></th></tr><tr><th align="center" valign="top" charoff="50">Deleted (n&#x02009;=&#x02009;30)</th><th align="center" valign="top" charoff="50">Normal (n&#x02009;=&#x02009;368)</th><th align="center" valign="top" charoff="50"><italic>P</italic>-value*</th></tr></thead><tbody valign="top"><tr><td colspan="4" align="left" valign="top" charoff="50">Age, y</td></tr><tr><td align="left" valign="top" charoff="50">&#x02003;Mean (SD)</td><td align="center" valign="top" charoff="50">53.3 (12)</td><td align="center" valign="top" charoff="50">42.3 (13.2)</td><td align="center" valign="top" charoff="50">&#x0003c;0.001</td></tr><tr><td colspan="4" align="left" valign="top" charoff="50">Gender, %</td></tr><tr><td align="left" valign="top" charoff="50">&#x02003;Male</td><td align="center" valign="top" charoff="50">50.0</td><td align="center" valign="top" charoff="50">55.6</td><td align="center" valign="top" charoff="50">0.681</td></tr><tr><td align="left" valign="top" charoff="50">&#x02003;Female</td><td align="center" valign="top" charoff="50">50.0</td><td align="center" valign="top" charoff="50">44.4</td><td align="center" valign="top" charoff="50">&#x000a0;</td></tr><tr><td colspan="4" align="left" valign="top" charoff="50">Histological subtype, %</td></tr><tr><td align="left" valign="top" charoff="50">&#x02003;Astrocytoma</td><td align="center" valign="top" charoff="50">53.4</td><td align="center" valign="top" charoff="50">34.6</td><td align="center" valign="top" charoff="50">0.092</td></tr><tr><td align="left" valign="top" charoff="50">&#x02003;Oligoastrocytoma</td><td align="center" valign="top" charoff="50">23.3</td><td align="center" valign="top" charoff="50">26.1</td><td align="center" valign="top" charoff="50">&#x000a0;</td></tr><tr><td align="left" valign="top" charoff="50">&#x02003;Oligodendroglioma</td><td align="center" valign="top" charoff="50">23.3</td><td align="center" valign="top" charoff="50">40.3</td><td align="center" valign="top" charoff="50">&#x000a0;</td></tr><tr><td colspan="4" align="left" valign="top" charoff="50">Histological grade, %</td></tr><tr><td align="left" valign="top" charoff="50">&#x02003;II</td><td align="center" valign="top" charoff="50">16.7</td><td align="center" valign="top" charoff="50">50.4</td><td align="center" valign="top" charoff="50">&#x0003c;<bold>0.001</bold></td></tr><tr><td align="left" valign="top" charoff="50">&#x02003;III</td><td align="center" valign="top" charoff="50">83.3</td><td align="center" valign="top" charoff="50">49.6</td><td align="center" valign="top" charoff="50">&#x000a0;</td></tr></tbody></table><table-wrap-foot><fn id="t1-fn1"><p>*Two-sided Student&#x02019;s t-test (continuous variables) or the chi-square test (categorical variable).</p></fn></table-wrap-foot></table-wrap><table-wrap position="float" id="t2"><label>Table 2</label><caption><title>Clinicopathological features according to the expression of <italic>NFKBIA.</italic></title></caption><table frame="hsides" rules="groups" border="1"><colgroup><col align="left"/><col align="center"/><col align="center"/><col align="center"/></colgroup><thead valign="bottom"><tr><th rowspan="3" align="left" valign="middle" charoff="50">Variables</th><th colspan="3" align="center" valign="top" charoff="50"><italic>NFKBIA</italic> expression<hr/></th></tr><tr><th align="center" valign="top" charoff="50">Low (n&#x02009;=&#x02009;208)</th><th align="center" valign="top" charoff="50">High (n&#x02009;=&#x02009;209)</th><th align="center" valign="top" charoff="50"><italic>P</italic>-value*</th></tr></thead><tbody valign="top"><tr><td colspan="4" align="left" valign="top" charoff="50">Age, y</td></tr><tr><td align="left" valign="top" charoff="50">&#x02003;Mean (SD)</td><td align="center" valign="top" charoff="50">43.4 (14.2)</td><td align="center" valign="top" charoff="50">42.8 (12.6)</td><td align="center" valign="top" charoff="50">0.671</td></tr><tr><td colspan="4" align="left" valign="top" charoff="50">Gender, %</td></tr><tr><td align="left" valign="top" charoff="50">&#x02003;Male</td><td align="center" valign="top" charoff="50">47.1</td><td align="center" valign="top" charoff="50">42.6</td><td align="center" valign="top" charoff="50">0.402</td></tr><tr><td align="left" valign="top" charoff="50">&#x02003;Female</td><td align="center" valign="top" charoff="50">52.9</td><td align="center" valign="top" charoff="50">57.4</td><td align="center" valign="top" charoff="50">&#x000a0;</td></tr><tr><td colspan="4" align="left" valign="top" charoff="50">Histological subtype, %</td></tr><tr><td align="left" valign="top" charoff="50">&#x02003;Astrocytoma</td><td align="center" valign="top" charoff="50">39.9</td><td align="center" valign="top" charoff="50">32.0</td><td align="center" valign="top" charoff="50">0.173</td></tr><tr><td align="left" valign="top" charoff="50">&#x02003;Oligoastrocytoma</td><td align="center" valign="top" charoff="50">26.0</td><td align="center" valign="top" charoff="50">25.8</td><td align="center" valign="top" charoff="50">&#x000a0;</td></tr><tr><td align="left" valign="top" charoff="50">&#x02003;Oligodendroglioma</td><td align="center" valign="top" charoff="50">34.1</td><td align="center" valign="top" charoff="50">42.2</td><td align="center" valign="top" charoff="50">&#x000a0;</td></tr><tr><td colspan="4" align="left" valign="top" charoff="50">Histological grade, %</td></tr><tr><td align="left" valign="top" charoff="50">&#x02003;II</td><td align="center" valign="top" charoff="50">42.3</td><td align="center" valign="top" charoff="50">53.6</td><td align="center" valign="top" charoff="50"><bold>0.027</bold></td></tr><tr><td align="left" valign="top" charoff="50">&#x02003;III</td><td align="center" valign="top" charoff="50">57.7</td><td align="center" valign="top" charoff="50">46.4</td><td align="center" valign="top" charoff="50">&#x000a0;</td></tr></tbody></table><table-wrap-foot><fn id="t2-fn1"><p>*Two-sided Student&#x02019;s t-test (continuous variables) or the chi-square test (categorical variable).</p></fn></table-wrap-foot></table-wrap><table-wrap position="float" id="t3"><label>Table 3</label><caption><title>Univariate Cox regression analysis of 5-year survival and 5-year recurrence-free survival.</title></caption><table frame="hsides" rules="groups" border="1"><colgroup><col align="left"/><col align="center"/><col align="center"/><col align="center"/><col align="center"/></colgroup><thead valign="bottom"><tr><th rowspan="3" align="left" valign="middle" charoff="50">Variables</th><th colspan="2" align="center" valign="top" charoff="50">5-year survival<hr/></th><th colspan="2" align="center" valign="top" charoff="50">5-year RFS<hr/></th></tr><tr><th align="center" valign="top" charoff="50">HR (95% CI)</th><th align="center" valign="top" charoff="50"><italic>P</italic>-value</th><th align="center" valign="top" charoff="50">HR (95% CI)</th><th align="center" valign="top" charoff="50"><italic>P</italic>-value</th></tr></thead><tbody valign="top"><tr><td align="left" valign="top" charoff="50">Age</td><td align="center" valign="top" charoff="50">1.084 (1.06&#x02013;1.108)</td><td align="center" valign="top" charoff="50">&#x0003c;0.001</td><td align="center" valign="top" charoff="50">1.008 (0.989&#x02013;1.029)</td><td align="center" valign="top" charoff="50">0.371</td></tr><tr><td colspan="5" align="left" valign="top" charoff="50">Gender</td></tr><tr><td align="left" valign="top" charoff="50">&#x02003;Female vs. Male</td><td align="center" valign="top" charoff="50">1.011 (0.578&#x02013;1.769)</td><td align="center" valign="top" charoff="50">0.968</td><td align="center" valign="top" charoff="50">0.824 (0.522&#x02013;1.302)</td><td align="center" valign="top" charoff="50">0.408</td></tr><tr><td colspan="5" align="left" valign="top" charoff="50">Histological subtype</td></tr><tr><td align="left" valign="top" charoff="50">&#x02003;Astrocytoma vs. Oligodendroglioma</td><td align="center" valign="top" charoff="50">0.463 (0.244&#x02013;0.881)</td><td align="center" valign="top" charoff="50">0.019</td><td align="center" valign="top" charoff="50">0.795 (0.462&#x02013;1.370)</td><td align="center" valign="top" charoff="50">0.409</td></tr><tr><td align="left" valign="top" charoff="50">&#x02003;Astrocytoma vs. Oligoastrocytoma</td><td align="center" valign="top" charoff="50">0.468 (0.224&#x02013;0.976)</td><td align="center" valign="top" charoff="50">0.042</td><td align="center" valign="top" charoff="50">0.828 (0.455&#x02013;1.509)</td><td align="center" valign="top" charoff="50">0.539</td></tr><tr><td colspan="5" align="left" valign="top" charoff="50">Histological grade</td></tr><tr><td align="left" valign="top" charoff="50">&#x02003;II vs. III</td><td align="center" valign="top" charoff="50">1.708 (2.59&#x02013;11.77)</td><td align="center" valign="top" charoff="50">&#x0003c;<bold>0.001</bold></td><td align="center" valign="top" charoff="50">1.348 (0.848&#x02013;2.141)</td><td align="center" valign="top" charoff="50">0.206</td></tr><tr><td colspan="5" align="left" valign="top" charoff="50"><italic>NFKBIA</italic> dosage</td></tr><tr><td align="left" valign="top" charoff="50">&#x02003;Normal vs. Deleted</td><td align="center" valign="top" charoff="50">6.537 (3.261&#x02013;13.11)</td><td align="center" valign="top" charoff="50">&#x0003c;<bold>0.001</bold></td><td align="center" valign="top" charoff="50">3.65 (1.653&#x02013;8.06)</td><td align="center" valign="top" charoff="50"><bold>0.001</bold></td></tr><tr><td align="left" valign="top" charoff="50">&#x02003;<italic>NFKBIA</italic> expression</td><td align="center" valign="top" charoff="50">0.470 (0.322&#x02013;0.685)</td><td align="center" valign="top" charoff="50">&#x0003c;<bold>0.001</bold></td><td align="center" valign="top" charoff="50">0.584 (0.420&#x02013;0.813)</td><td align="center" valign="top" charoff="50"><bold>0.001</bold></td></tr></tbody></table><table-wrap-foot><fn id="t3-fn1"><p>RFS, recurrence-free survival. HR, hazard ratio; CI, confidence interval.</p></fn></table-wrap-foot></table-wrap><table-wrap position="float" id="t4"><label>Table 4</label><caption><title>Multivariate Cox regression analysis of 5-year survival and 5-year recurrence-free survival according to the dosage of <italic>NFKBIA</italic>.</title></caption><table frame="hsides" rules="groups" border="1"><colgroup><col align="left"/><col align="center"/><col align="center"/><col align="center"/><col align="center"/></colgroup><thead valign="bottom"><tr><th rowspan="3" align="left" valign="middle" charoff="50">Variables</th><th colspan="2" align="center" valign="top" charoff="50">5-year survival<hr/></th><th colspan="2" align="center" valign="top" charoff="50">5-year RFS<hr/></th></tr><tr><th align="center" valign="top" charoff="50">HR (95% CI)</th><th align="center" valign="top" charoff="50"><italic>P</italic>-value</th><th align="center" valign="top" charoff="50">HR (95% CI)</th><th align="center" valign="top" charoff="50"><italic>P</italic>-value</th></tr></thead><tbody valign="top"><tr><td align="left" valign="top" charoff="50">Age</td><td align="center" valign="top" charoff="50">1.084 (1.056&#x02013;1.112)</td><td align="center" valign="top" charoff="50">&#x0003c;<bold>0.001</bold></td><td align="center" valign="top" charoff="50">1.013 (0.992&#x02013;1.034)</td><td align="center" valign="top" charoff="50">0.208</td></tr><tr><td colspan="5" align="left" valign="top" charoff="50">Gender</td></tr><tr><td align="left" valign="top" charoff="50">&#x02003;Female vs. Male</td><td align="center" valign="top" charoff="50">0.928 (0.520&#x02013;1.656)</td><td align="center" valign="top" charoff="50">0.802</td><td align="center" valign="top" charoff="50">0.901 (0.542&#x02013;1.500)</td><td align="center" valign="top" charoff="50">0.690</td></tr><tr><td colspan="5" align="left" valign="top" charoff="50">Histological subtype</td></tr><tr><td align="left" valign="top" charoff="50">&#x02003;Astrocytoma vs. Oligodendroglioma</td><td align="center" valign="top" charoff="50">0.423 (0.209&#x02013;0.853)</td><td align="center" valign="top" charoff="50">0.016</td><td align="center" valign="top" charoff="50">0.729 (0.390 &#x02013; 1.363)</td><td align="center" valign="top" charoff="50">0.322</td></tr><tr><td align="left" valign="top" charoff="50">&#x02003;Astrocytoma vs. Oligoastrocytoma</td><td align="center" valign="top" charoff="50">0.542 (0.250&#x02013;1.177)</td><td align="center" valign="top" charoff="50">0.122</td><td align="center" valign="top" charoff="50">0.969 (0.509&#x02013;1.842)</td><td align="center" valign="top" charoff="50">0.923</td></tr><tr><td colspan="5" align="left" valign="top" charoff="50">Histological grade</td></tr><tr><td align="left" valign="top" charoff="50">&#x02003;II vs. III</td><td align="center" valign="top" charoff="50">2.923 (1.308&#x02013;6.528)</td><td align="center" valign="top" charoff="50"><bold>0.008</bold></td><td align="center" valign="top" charoff="50">1.156 (0.669&#x02013;1.998)</td><td align="center" valign="top" charoff="50">0.602</td></tr><tr><td colspan="5" align="left" valign="top" charoff="50"><italic>NFKBIA</italic> dosage</td></tr><tr><td align="left" valign="top" charoff="50">&#x02003;Normal vs. Deleted</td><td align="center" valign="top" charoff="50">2.158 (1.018&#x02013;4.572)</td><td align="center" valign="top" charoff="50"><bold>0.016</bold></td><td align="center" valign="top" charoff="50">3.111 (1.323&#x02013;7.318)</td><td align="center" valign="top" charoff="50"><bold>0.009</bold></td></tr></tbody></table><table-wrap-foot><fn id="t4-fn1"><p>RFS, recurrence-free survival. HR, hazard ratio; CI, confidence interval.</p></fn></table-wrap-foot></table-wrap><table-wrap position="float" id="t5"><label>Table 5</label><caption><title>Multivariate Cox regression analysis of 5-year survival and 5-year recurrence-free survival according to the expression of <italic>NFKBIA</italic>.</title></caption><table frame="hsides" rules="groups" border="1"><colgroup><col align="left"/><col align="center"/><col align="center"/><col align="center"/><col align="center"/></colgroup><thead valign="bottom"><tr><th rowspan="3" align="left" valign="middle" charoff="50">Variables</th><th colspan="2" align="center" valign="top" charoff="50">5-year survival<hr/></th><th colspan="2" align="center" valign="top" charoff="50">5-year RFS<hr/></th></tr><tr><th align="center" valign="top" charoff="50">HR (95% CI)</th><th align="center" valign="top" charoff="50"><italic>P</italic>-value</th><th align="center" valign="top" charoff="50">HR (95% CI)</th><th align="center" valign="top" charoff="50"><italic>P</italic>-value</th></tr></thead><tbody valign="top"><tr><td align="left" valign="top" charoff="50">Age</td><td align="center" valign="top" charoff="50">1.087 (1.061&#x02013;1.144)</td><td align="center" valign="top" charoff="50">&#x0003c;<bold>0.001</bold></td><td align="center" valign="top" charoff="50">1.013 (0.993&#x02013;1.034)</td><td align="center" valign="top" charoff="50">0.196</td></tr><tr><td colspan="5" align="left" valign="top" charoff="50">Gender</td></tr><tr><td align="left" valign="top" charoff="50">&#x02003;Female vs. Male</td><td align="center" valign="top" charoff="50">1.057 (0.596&#x02013;1.875)</td><td align="center" valign="top" charoff="50">0.847</td><td align="center" valign="top" charoff="50">0.902 (0.552&#x02013;1.474)</td><td align="center" valign="top" charoff="50">0.681</td></tr><tr><td colspan="5" align="left" valign="top" charoff="50">Histological subtype</td></tr><tr><td align="left" valign="top" charoff="50">&#x02003;Astrocytoma vs. Oligodendroglioma</td><td align="center" valign="top" charoff="50">0.394 (0.200&#x02013;0.774)</td><td align="center" valign="top" charoff="50"><bold>0.006</bold></td><td align="center" valign="top" charoff="50">0.694 (0.377&#x02013;1.277)</td><td align="center" valign="top" charoff="50">0.240</td></tr><tr><td align="left" valign="top" charoff="50">&#x02003;Astrocytoma vs. Oligoastrocytoma</td><td align="center" valign="top" charoff="50">0.480 (0.223&#x02013;1.031)</td><td align="center" valign="top" charoff="50">0.060</td><td align="center" valign="top" charoff="50">0.842 (0.447&#x02013;1.583)</td><td align="center" valign="top" charoff="50">0.593</td></tr><tr><td colspan="5" align="left" valign="top" charoff="50">Histological grade</td></tr><tr><td align="left" valign="top" charoff="50">&#x02003;II vs. III</td><td align="center" valign="top" charoff="50">2.596 (1.159&#x02013;5.814)</td><td align="center" valign="top" charoff="50"><bold>0.020</bold></td><td align="center" valign="top" charoff="50">1.129 (0.657&#x02013;1.939)</td><td align="center" valign="top" charoff="50">0.659</td></tr><tr><td align="left" valign="top" charoff="50">&#x02003;<italic>NFKBIA</italic> expression</td><td align="center" valign="top" charoff="50">0.544 (0.367&#x02013;0.806)</td><td align="center" valign="top" charoff="50"><bold>0.002</bold></td><td align="center" valign="top" charoff="50">0.616 (0.437&#x02013;0.868)</td><td align="center" valign="top" charoff="50"><bold>0.005</bold></td></tr></tbody></table><table-wrap-foot><fn id="t5-fn1"><p>RFS, recurrence-free survival. HR, hazard ratio; CI, confidence interval.</p></fn></table-wrap-foot></table-wrap></floats-group></article>